nda

pulmonary arterial hypertension
#FDA #Hypertension #nda

FDA accepts NDA for hypertension treatment option 

The US Food and Drug Administration (FDA) has accepted a New Drug Application (NDA) for hypertension drug lorundrostat.  Biopharmaceutical company Mineralys Therapeutics announced the NDA for lorundrostat was accepted for the treatment of adult patients with hypertension in combination with other antihypertensive drugs. The FDA has assigned a Prescription Drug User Fee Act… Read More

#News #Regulatory

Cancer research
#Clinical trial #FDA #nda

Relief Therapeutics announces positive results for PKU treatment 

Biopharmaceutical company Relief Therapeutics has announced positive results from its bioequivalence study of RLF-OD032 for the treatment of phenylketonuria (PKU).  The study achieved its primary pharmacokinetic endpoints, demonstrating that RLF-OD032 is bioequivalent to KUVAN Powder, the reference listed drug, as defined by the US Food and Drug Administration… Read More

#News